July 14, 2014 2:41 AM ET

Healthcare Equipment and Supplies

Company Overview of Semprus BioSciences Corp.

Company Overview

Semprus BioSciences Corp., a biomedical company, focuses on providing complication-free medical devices. The company’s Semprus Sustain technology is a permanent non-leaching biomaterial modification to the device surface that prevents medical complications, such as infection, blood clots, improper healing, and cell overgrowth. It focuses on enabling permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheters with a single surface modification. Semprus BioSciences also focuses on developing new products to reduce microbial adhesion, deliver drugs, bind with agents in the bloodstream, or provide improved accuracy for diagnostics. The company was formerly kno...

One Kendall Square

Building 1400 West

1st Floor

Cambridge, MA 02139

United States

Founded in 2006

Phone:

617-577-7755

Fax:

617-577-7756

Key Executives for Semprus BioSciences Corp.

Co-Founder and Chief Technology Officer
Co-Founder
Age: 65
Vice President of Business Development
Vice President of Product Development
Compensation as of Fiscal Year 2014.

Semprus BioSciences Corp. Key Developments

Semprus BioSciences Corp. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 11:00 AM

Semprus BioSciences Corp. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 11:00 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: David L. Lucchino, Co-Founder, Chief Executive Officer and Director.

Semprus BioSciences Corp. Receives FDA 510(k) Clearance for Nylus PICC with Semprus Sustain Technology

Teleflex Incorporated has announced that Semprus BioSciences Corp. has been granted 510(k) clearance for the company's innovative vascular access catheter, the Nylus(TM) Peripherally Inserted Central Catheter (PICC) with Semprus Sustain(TM) Technology. The Nylus PICC is indicated to provide peripheral access to the central venous system for infusion, intravenous therapy, blood sampling, central venous pressure monitoring and power injection of contrast media. The FDA clearance follows the product's European market clearance in July, 2012. The Nylus PICC uses a long-lasting polymer surface modification designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. This provides benefits to the patient, the caregiver and the health care system. The Nylus PICC has been shown to reduce platelet adhesion and thrombus accumulation by 99% in both in vitro and acute animal testing.

Semprus BioSciences Corp. Presents at The 14th Annual Southeast BIO (SEBIO) Investor Forum, Nov-01-2012 08:30 AM

Semprus BioSciences Corp. Presents at The 14th Annual Southeast BIO (SEBIO) Investor Forum, Nov-01-2012 08:30 AM. Venue: The Breakers Resort, Palm Beach, Florida, United States. Speakers: David L. Lucchino, Co-Founder, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Apira Science, Inc. United States
LightWave Ablation Systems, Inc. United States
Myotech, LLC United States
Eye Care One, Inc. United States
Martha Coker Home Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Semprus BioSciences Corp., please visit www.semprusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.